设为首页         

资讯内容 Content

[ESC2009]单片复方制剂(SPC)倍博特在高血压治疗中的应用和优势--Weir教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:单片复方制剂 高血压治疗 倍博特 阿利吉仑 


International Circulation:  The period to reach the target blood pressure with valsartan amlodipine single pill combation is shorter than with monotherapy. Do you consider that valsartan amlodipine single pill(Exforge) the good choice for the patients with high risk need to control blood pressure optimally in short time?

《国际循环》:缬沙坦氨氯地平单片联合达到目标血压的时间较单药治疗短。您是否认为缬沙坦氨氯地平单片(Exforge®)是需在短时间内使血压得到最佳控制的高危高血压患者的良好选择?

Professor Weir:  There is more and more evidence that promptness in controlling blood pressure is in fact important.  You know the old story was start low go slow and you may not ever reach appropriate targets.  In this case, we do have enough evidence now to show that the timely control of blood pressure does make a difference and it is quite evident using this type of single pill combination particularly right at the outset does facilitate earlier control of both diastolic and systolic blood pressure.  So from that sense, it does make sense.

Weir教授:越来越多的证据显示,迅速控制血压非常重要。我们知道,以前的说法是小剂量开始且缓慢加量,但可能从未达到合适的目标。针对这种情况,我们现在有足够的证据显示,及时控制血压确实有影响。很显然,应用尤其是一开始即应用这种单片联合药物确实促使收缩压和舒张压更早得到控制。因此,从这种意义上讲,这种单片联合确实有意义。



上一页  [1]  [2]  [3]  [4]  [5]  [6]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved